Cellectis Presents Preclinical .HEAL-101 Data At ESGCT 2026 Showing Up To 70% In Vivo Human APOC3 Editing, 75% Triglyceride Reduction In Mouse Model; Plans Phase 1 China Trial
Share
Why It Matters
Cellectis tested a new gene therapy that cut triglycerides in mice. The early results look promising, so they plan human trials in China soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.